TABLE 2.

BATF expression difference between responders and non 32 responders in various data sets.

No	PMID	Cancer type	Group	Drug	Responder	Non-Responder	Log2 (fold change)	p value
1	26997480	Melanoma	All	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	−0.215	0.695
			MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.735	0.665
			Non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	−0.903	0.461
2	28552987	Urothelial cancer	All	Anti-PD-L1 (atezolizumab)	9	16	0.648	0.213
			Smoking	Anti-PD-L1 (atezolizumab)	5	9	0.192	0.872
			Non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.213	0.329
3	29033130	Melanoma	All	Anti-PD-1 (nivolumab)	26	23	0.609	0.276
			NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.845	0.355
			NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.403	0.673
4	29301960	Clear cell renal cell carcinoma	All	Anti-PD-1 (nivolumab)	4	8	2.049	0.114
			VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
			Non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.363	0.503
5	29443960	Urothelial cancer	All	Anti-PD-L1 (atezolizumab)	68	230	−0.065	0.64